Authors' objectives: To evaluate the efficacy, safety, cost-effectiveness and organisational issue related to Versajet hydrosurgery system for debridement.

Authors' results and conclusions: There was substantial evidence on Versajet hydrosurgery system for debridement. However, some studies have high risk of bias due to inappropriate randomisation sequence generation and selective measurement of the outcome, hence varying the quality of the included trials. Nevertheless, the evidence showed that Versajet may reduce the healing and operative time to treatment, improve quality of scar or dermal plane efficacy, and optimise the need for grafting. The Versajet hydrosurgery system may reduce the blood loss and transfusion, and decrease the infection rate. Even though there was one serious adverse event and some mild or moderate adverse events were reported, none of them were related to Versajet hydrosurgery system. The latest version of Versajet hydrosurgery system had received 510(k) from United States Food and Drug Administration and was Conformité Européenne (CE) marked in 2011 before launched in 2012. The hydrosurgery system also had been approved by Medical Device Authority Malaysia in 2018. There was no significant difference between the two groups in terms of cost of the first operative procedure, cost of surgical procedures during the study, cost of study treatment or cost to achieve stable wound closure. Approximately, the price for one set of the latest version of Versajet hydrosurgery system was USD$8,478.66

Authors' recommendations: Versajet hydrosurgery system may be used as an option for wound debridement.

Authors' methods: Electronic databases were searched through the Ovid interface; Ovid MEDLINE(R) In-Process & Other Non-Indexed Citations and Ovid MEDLINE(R) 1946 to 13 August 2021, Ovid MEDLINE(R) and Epub Ahead of Print, In-Process, In-Data-Review & Other Non-Indexed Citations and Daily 1946 to August 13, 2021, Ovid MEDLINE(R) and In-Process, In-Data-Review & Other Non-Indexed Citations 1946 to August 13, 2021, Ovid MEDLINE(R) and Epub Ahead of Print, In-Process, In-Data-Review & Other Non-Indexed Citations and Daily 2017 to August 13, 2021, Ovid MEDLINE(R) 1946 to August Week 1 2021, Ovid MEDLINE(R) 1996 to August Week 1 2021, Ovid MEDLINE(R) Epub Ahead of Print August 13, 2021, Ovid MEDLINE(R) Daily Update August 13, 2021 and Ovid MEDLINE(R) 2017 to August Week 1 2021. Searches were also run in PubMed, INAHTA, Cochrane Library and US Food and Drug Administration. Google was used to search for additional web-based materials and information. Additional articles were identified from reviewing the references of retrieved articles. Last search was conducted on 20 August 2021.

Authors' identified further research: None

Project Status: Completed

Year Published: 2021

URL for published report: https://www.moh.gov.my/index.php/database_stores/store_view_page/30/395

Requestor: Ministry of Health

English language abstract: An English language summary is available

Publication Type: Mini HTA

Country: Malaysia

Organisation Name: Malaysian Health Technology Assessment

Contact Address: Malaysian Health Technology Assessment Section, Ministry of Health Malaysia, Federal Government Administrative Centre, Level 4, Block E1, Parcel E, 62590 Putrajaya Malaysia Tel: +603 8883 1229

Contact Name: htamalaysia@moh.gov.my

Contact Email: htamalaysia@moh.gov.my

Copyright: Malaysian Health Technology Assessment Section (MaHTAS)